Open AccessEUS-through-the-needle microbiopsy forceps in pancreatic cystic lesions: A systematic review
Author(s) -
Daniel Vasile Balaban,
Irina M. Cazacu,
Larisa Pinte,
Mariana Jinga,
Manoop S. Bhutani,
Adrian Săftoiu
Publication year - 2021
Publication title -
endoscopic ultrasound
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.883
H-Index - 24
eISSN - 2303-9027
pISSN - 2226-7190
DOI - 10.4103/eus.eus_23_20
Subject(s) - medicine , forceps , radiology , biopsy , systematic review , medline , sampling (signal processing) , endoscopic ultrasound , medical physics , general surgery , surgery , filter (signal processing) , political science , computer science , law , computer vision
Pancreatic cystic lesions (PCLs) are being increasingly encountered in clinical practice, and sometimes, they can represent a diagnostic challenge. Recently, a through-the-needle micro forceps biopsy (MFB) device was introduced in the endosonography practice to facilitate EUS-guided sampling of PCLs. The aim was to perform a systematic review of studies evaluating the technical aspects, safety, and efficacy of the EUS-guided MFB for PCLs. A literature search was performed in three major databases, PubMed, Embase, and Web of Science in September 2019 using the search terms: "through-the-needle," "biopsy forceps," "microforceps," "endoscopic ultrasound," and "endosonography." Case reports and case series with <10 patients were excluded from the analysis. Altogether nine studies reporting on 463 patients were included in our systematic review. The mean age of the patients was 68.3 years, with a slight female predominance (60.9%). Most of the cysts were located in the body/tail of the pancreas (61.2%), with an overall mean size of 33 mm. The technical success of EUS-guided MFB was reported in 98.5%. The tissue acquisition yield reported was 88.2%, and the diagnostic accuracy was 68.6%. Adverse events were reported in 9.7%. EUS-guided MFB is technically feasible, safe, and has a high diagnostic accuracy for PCLs.